Cybin Inc. (OTCMKTS: CYBN) is a biotechnology company dedicated to the research, development and commercialization of psychedelic-based therapeutics for the treatment of various mental health conditions. The company leverages its proprietary drug discovery engine and novel delivery platforms to create next-generation psychedelic molecules designed to improve safety, efficacy and patient experience. Cybin’s pipeline includes psilocybin-derived compounds, 5-MeO-DMT analogs, LSD-inspired molecules and associated microdosing formulations.
Central to Cybin’s strategy is the DeNovo™ platform, which optimizes the pharmacological profiles of psychedelic agents while advancing scalable manufacturing processes. The company’s preclinical and clinical programs encompass multiple indications, including major depressive disorder, anxiety, insomnia and substance use disorders. Cybin has initiated Phase 1 and Phase 2 clinical trials in collaboration with academic and research institutions to evaluate its lead candidates under controlled settings.
Founded in 2019 and headquartered in Toronto, Canada, Cybin maintains additional facilities in the United States for research, development and manufacturing. The company has forged partnerships with universities and contract research organizations to support exploratory studies and regulatory filings. Through its integrated approach, Cybin aims to address unmet medical needs and redefine standards of care in psychiatric medicine.
Under the leadership of Chief Executive Officer Doug Drysdale, Cybin continues to build a multidisciplinary team spanning chemistry, pharmacology, clinical operations and commercial development. The company remains focused on advancing its pipeline, securing intellectual property rights and preparing for eventual product launch upon regulatory approval.
AI Generated. May Contain Errors.
